A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

This Phase 2, randomised, multicentre, parallel-group treatment, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of subcutaneous (SC) MEDI0618 in participants with episodic migraine. The study includes a cohort of participants who have a history of unsuccessful treatment with \>= 2 small molecule migraine preventive treatments from different classes per investigator's judgement and are eligible to receive anti-calcitonin gene-related peptide (aCGRP) therapy but have not yet done so (aCGRP-naïve \[aCGRP-N\]); The study also includes a smaller cohort of participants who have failed one or more aCGRP therapies (aCGRP-IRs) used for preventative treatment and have a history of unsuccessful treatment with \>= 2 small molecule migraine preventive treatments from different classes.